Retrospective Study
Copyright ©The Author(s) 2025.
World J Clin Oncol. Apr 24, 2025; 16(4): 102735
Published online Apr 24, 2025. doi: 10.5306/wjco.v16.i4.102735
Table 1 Clinical and pathologic characteristics in patients with hepatocellular carcinoma, n (%)
Clinicopathologic variable
Positive
Negative
P value
Sex
    Male24 (42.9)15 (26.8)0.315
    Female8 (14.3)9 (16.1)
Age55.18 ± 10.5154.91 ± 8.250.154
BMI22.56 ± 3.6323.06 ± 3.030.585
AFP3941.72 ± 16289.448512.91 ± 25755.920.124
APTT12.72 ± 1.7013.35 ± 2.600.107
TBil16.68 ± 9.0816.77 ± 11.090.689
ALB35.98 ± 5.9536.07 ± 5.170.780
AST81.80 ± 95.8162.92 ± 49.070.204
ALT67.83 ± 99.1962.30 ± 59.860.685
Tumor diameter4.88 ± 3.145.76 ± 2.740.651
Cirrhosis
    Yes27 (48.2)18 (32.1)0.384
    No5 (8.9)6 (10.7)
ECOG score
    017 (30.4)12 (21.4)0.893
    113 (23.2)11 (19.6)
    22 (3.6)1 (1.8)
Child-Pugh score
    A1 (1.8)0 (0)0.408
    B26 (46.4)18 (32.1)
    C5 (8.9)6 (10.7)
BCLC score
    A1 (1.8)1 (1.8)0.070
    B8 (14.3)13 (23.2)
    C23 (40.2)10 (17.9)
Portal hypertension
    Yes16 (28.6)12 (21.4)1.000
    No16 (28.6)12 (21.4)
Table 2 Univariate and multivariate analyses of factors predicting therapeutic efficacy (n = 56)
Clinicopathologic variable
OR
95%CI
P value
Univariate analysis
Age5.3080.594-47.4290.135
HBV infection2.2800.675-7.7050.185
AFP1.0001.000-1.0000.433
Vascular invasion0.6800.231-2.0010.484
Ascites0.9180.315-2.6790.876
RER0.0290.006-0.1280.000a
ALBI1.4000.070-28.1200.826
NLR26.6006.314-112.0540.000a
PLR7.2222.148-24.2880.001a
PNI3.6671.108-12.1370.033a
Multivariate analysis
NLR group (< 5 vs ≥ 5)21.7651.231-384.8770.036a
PLR group (< 300 vs ≥ 300)33.8571.261-909.2840.036a
PNI group (< 45 vs ≥ 45)73.3671.362-3951.4540.035a
RER group (< 9 vs ≥ 9)187.232.007-17464.6350.024a